^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2930
i
Other names: TQB2930
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
HER2 inhibitor
Related drugs:
8ms
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=154, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
gemcitabine • paclitaxel • capecitabine • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • culmerciclib (TQB3616) • TQB2930
10ms
A Study of TQB2930 for Injection Monotherapy or Combination Chemotherapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=89, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • Metastases
|
docetaxel • TQB2930
over2years
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers (clinicaltrials.gov)
P1, N=60, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
TQB2930
Share via
